{"name":"Belite Bio, Inc","slug":"belite-bio-inc","ticker":"","exchange":"","domain":"belitebio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BPN-14967","genericName":"BPN-14967","slug":"bpn-14967","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BPN-14967","genericName":"BPN-14967","slug":"bpn-14967","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWDVVT0I3X1p5NmhLaFpnNkMyMzEtX3pYb3RQd25VamMzbnlwVWFyTFFvVk9NaHhrY0tDSzFzQy1xaGpJdmxmdWJ6TW9EUjdPZFNWODNremFrZjUxX2NxZWpFMVIza2JVUFdvWXExMTV4MXBHY2REeUN4bmtRSmhYSy0yWVcybHZUaWNESGFNc042LWhHcTd4N3E1RFZnOFFWU0xIT1Q5SFMwTGhNRk9tay00MlRzcjdHLUFBamJNSXZmTzV2V1RxekhqU3poSl9F?oc=5","date":"2026-02-25","type":"regulatory","source":"BioCentury","summary":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision - BioCentury","headline":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNX3B2bzBNT3hINHFtTXRKVW1EVFVjUFo1OXYtdTJxQWZUNEJ4OC1tRW12cVRnYUJjRkRoYVZZUjdobnB4RWdQSXktN3V0ZE14b2RRYmxCUGRfckFxMzFVcXQ1R1MwNjNqWENKc3QtdUIzVkhQaDA3cjdEcTI1VXNiamRERDJZSXc2RWpnRTBFRmxXMUFiNGNmOFlKZmNNV1RWY2dFWS1uSTY0RkNuemxIcDY1RnJtRUtxRUQ5aDN5TFhhYWpGa3JNTTM4QVYta0tSZ2hLWmhhaFRXVFBTdTNONzN2MA?oc=5","date":"2026-02-19","type":"pipeline","source":"Barchart","summary":"Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart","headline":"Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSUhnblpfRjNid2xZb1JfWURtTlZEMkg5ZjBEcFFPRjd5VjRlN3BEQ3pWbXMwcUU5MmZGMFp0Z2dDSWRLUlRPVkJRQzI4ZmxXSU9uSHpSUlRhbHdtSW5GMmFHWjJOZWRTNlNsMjQzdGJZZXpuaEtjT0pFN3YyRGo3NkVsQ3pWYnFJYzFYc2dKOFdqX2JNOWFSY1FGcURkZEFBczRqMWZkNVE?oc=5","date":"2026-02-02","type":"trial","source":"BioWorld News","summary":"Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld News","headline":"Phase III wins propel Capricor, Belite and DBV higher in December","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNcExXbDRXdE1YUnpjU1pBS0UxeTdfb25MRWRWTjF5Q2ZkVGZqZ0hUckt4cmt5clVQaUZpVHQ5dnBYMzl0SDRfTEItdTZyc0lLVlA0VzdlZ2Eyc0ZOVHVqd0dETjNyaVNobkJBbGZldnhCYUE2R3VLS1ZyRWZMUUxHdjBMbTJTYzl2aFdBVXkwdjZrclVFMW55cU84SExpMEpLUm9wNHhWcHVUcjBMZEs1cXFJWXprYm9nV0pnbkJyVGlLc3ZFc2tmQW9RbndjRC1RY1VXaEZPUHBYMnUwWnhkd213ZWlOaHJRM3llY1BKOFlDSUQ1WjdFWTNKcGhoTlFxWnlsV3FtRlFSazlsS29palVfWWp2TDNNOENaR09YelpKMDVCbnR3M3VON1dNVmt3RkI0eVJ6U21wRE0xUzhrWFk4b3VpUFlMdjJOQ1BMbEFrREE?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart","summary":"Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics - B","headline":"Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveIn","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQk1YLVMtemVNQW4zb19SRTB3VUp0cEotaHladzFJNF9zdGdsTXcxQ0Q3bUpSQ1hldW5EX1FsVExBdnZKTDc0WXlkbTlud3lNblRmWmtwU3ZmYnRBU3oxVXludmpqM0NOalZUXzFXMDJJWE90M3BoRkRjdXdlNTJoNmNVclpmTzAtZVBlbEJRX0lqSkljRUJsVWlyaUxOVzNBSFB1ZGoxV0s3NFhhQV8yaThHU284cER3X1lR?oc=5","date":"2025-12-06","type":"trial","source":"BioCentury","summary":"Biocytogen lands on STAR as NASDAQ plays parlay data into cash: Finance Report - BioCentury","headline":"Biocytogen lands on STAR as NASDAQ plays parlay data into cash: Finance Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNMUJ1MVB1V0NPM0Q1NlFHSFlmQk01Nmt3Y0p2dUFUOGJYY3lCaXI1QUg5a3hxbXFXTzRaUDFEWVNkcHQyNGdPa2VTQy1jSUgzUHpJQTQ1c0VKQS1EeXZ1bkxNa2VyZWZuTURWbVdSTnVqZkFJcHdma21KZU40VWhHc0dxM3NreTRQb0NhdnhWQ1MzdEM2YUM5LU5HZTJnWEF0VXNybkFvTktpek1FRDlRS2tMZHY3ZnB0a2pqZHNpb2hTTm9QbW1UdGZ5TGg0SWZJU2E2UW95RE5yNzVRelNfaWZiUUd2clJRaXVv?oc=5","date":"2025-12-02","type":"trial","source":"Citeline News & Insights","summary":"Belite Bio’s Tinlarebant Shines In Phase III Stargardt Disease Trial - Citeline News & Insights","headline":"Belite Bio’s Tinlarebant Shines In Phase III Stargardt Disease Trial - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPMW5oSm9FZERWdHpoRV9VX0lkOVJHTDRIUE9rbGtnOGpwNzhhLVVqOVRBZ0FMemVPeHpxODVDZXZhV21pV2kwQWFPRU5QZG5mY1VyaDJwNG9JWkF4bVoxTzB2OU02YmxVZlVkbk04M1hwMWYxX2lLMlJDaHhucGlHMnBHTDB2VnhZRmlSU1BDWmJIaVVzSDRz?oc=5","date":"2025-12-01","type":"trial","source":"BioPharma Dive","summary":"Belite continues ascent as Stargardt drug hits mark in late-stage trial - BioPharma Dive","headline":"Belite continues ascent as Stargardt drug hits mark in late-stage trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"globenewswire.com","summary":"Geographic Atrophy Market to Surge Significantly During the - globenewswire.com","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQdjA4NjRPMVVoaVhDdmI1M2tpb0pyWlNpd3hTLVRNT01zNXVJc3NPQUpnUUEyV1pqZWNUN2lXdFdDX3dkcUNuTklNWU9NMzNQWGFXcGtRNF94QW5BTkhnYTBqN25OTmpBUVB4YXZTalg5UnN3TkNKZTdqa0ZyM2Njc21EX1MtQ0F6Y19pVHlNeXM0R21OV3dKaU01aHNOSzRBcV9CWWlmNFlHS25hQ3R5S1VKRjQyRmZWOWE2UHNRclJEakY4X1ZLekEtNmViMkFpclRzaldDT1RVaHBoanhNbUJBVG41NUxtTE1XUGxfa3JaZXQwUW54enQ1cFN3NmtwUTJHUlR0c0tHWHRLTDFKSlNuSnlEaUNRa2JqYXk5aGZKQTdOaTk0YTVyUnpKaHRiNDQwNmJkUFFJS2dhckhpN3BxNVkzRjg?oc=5","date":"2025-11-17","type":"pipeline","source":"globenewswire.com","summary":"Dry Age-related Macular Degeneration Market Poised for - globenewswire.com","headline":"Dry Age-related Macular Degeneration Market Poised for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBpVTVQeTBxSVBBVmlqR2VsMzRocjdyRm1zdDZZZGFDSmNpOXlPaDRqODZCbHN6NHgtb3B5R05jR2NCWlJTN2JSNE83SkFxYXlsa0o1TF9BUkRUdl9TWDl4c1ZncUgzc0lI?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE - MarketBeat","headline":"Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPaUJLUDhXcDg3M29ONVJjZjBheHZxbmw0Vmc2cllCbXpoY202cnJSaEZzUFMtUlk3ejBRdGlscUFDWllCdzJTOTY4eXc1RkNnZlhvZXhyWkRuSm9qZ0JPRl94dVZhNUFRb3BILThaSW5XOTJabk1iREszOXhDNnVtRW00RDhvWWlrUjhORldadlF4Zy1Cc2R2NA?oc=5","date":"2024-11-20","type":"pipeline","source":"Seeking Alpha","summary":"Belite Bio: Interesting Science, But Quite A Few Worries (NASDAQ:BLTE) - Seeking Alpha","headline":"Belite Bio: Interesting Science, But Quite A Few Worries (NASDAQ:BLTE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFA0VXFEVDhSd0hGeDlIbnF1NjFobTRXRDdjaUxoQmtFemlCb2dsbjhyRlRZODV0cDg1Qk91VDl6dWtCZVBmcU1VMnpRNzJIY191N0E?oc=5","date":"2023-05-30","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Belite Bio, Inc (BLTE) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Belite Bio, Inc (BLTE) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}